BMO Capital analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $127 to $129.
Uncategorized
BMO Capital Maintains Outperform on AbbVie, Raises Price Target to $129
BMO Capital analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $127 to $129.
Related Posts
Forest Road Acquisition Corp. Stockholders Approve Proposed Merger With The Beachbody Company and Myx Fitness, Creating the Leading Subscription Health and Wellness Company for the Mass Market
Forest Road Acquisition Corp. (NYSE:FRX) ("Forest Road") today announced that its stockholders have voted to approve the proposed three-way business combination (the "Business Combination") with The
US Recession Risk At Its Highest In 40 Years: Why Is The Stock Market Ignoring The Economy?
The New York Fed's U.S.
AMMO Awarded US DoD Contract For Development And Manufacture Of Signature-On-Target Rounds
AMMO, Inc. (NASDAQ:POWW) has been awarded a contract by the Irregular Warfare Technical Support Directorate (IWTSD), formerly CTTSO, operating under the…